Alan Colowick

Alan Colowick is a Managing Director at Matrix Capital Management, an investment fund focused on technology and life sciences. Prior to joining Matrix, Dr. Colowick was the Chairman of VelosBio until its acquisition by Merck in December 2020, and the Chairman of Principia Biopharma until its acquisition by Sanofi in September 2020. Dr. Colowick was the CEO of Gloucester Pharmaceuticals until it was acquired by Celgene, and he held executive positions at Celgene, Geron, Threshold Pharmaceuticals and Amgen.